Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Sutro Biopharma Inc (STRO)

Sutro Biopharma Inc (STRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 239,656
  • Shares Outstanding, K 81,794
  • Annual Sales, $ 153,730 K
  • Annual Income, $ -106,790 K
  • 60-Month Beta 1.24
  • Price/Sales 1.55
  • Price/Cash Flow N/A
  • Price/Book 1.86
Trade STRO with:

Options Overview Details

View History
  • Implied Volatility 101.10% ( -147.46%)
  • Historical Volatility 74.76%
  • IV Percentile 45%
  • IV Rank 34.01%
  • IV High 251.36% on 03/20/24
  • IV Low 23.64% on 06/04/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 61
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 1,901
  • Open Int (30-Day) 1,598

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.76
  • Number of Estimates 8
  • High Estimate -0.09
  • Low Estimate -1.04
  • Prior Year -0.64
  • Growth Rate Est. (year over year) -18.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.76 +6.52%
on 06/26/24
4.44 -33.78%
on 06/03/24
-1.28 (-30.41%)
since 05/31/24
3-Month
2.76 +6.52%
on 06/26/24
5.88 -50.00%
on 04/02/24
-2.38 (-44.79%)
since 04/01/24
52-Week
2.01 +46.63%
on 11/13/23
6.13 -52.04%
on 03/28/24
-1.71 (-36.77%)
since 06/30/23

Most Recent Stories

More News
Why Investors Are Suddenly Excited About Vaxcyte

Vaxcyte, Inc. is a small cap biotech company that catapulted back to mid-cap land with a stunning 110% surge — and may not be done yet.

PCVX : 75.46 (-0.07%)
PFE : 28.40 (+1.50%)
MRNA : 118.59 (-0.13%)
STRO : 2.97 (+1.37%)
MRK : 127.60 (+3.07%)
Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones

- Collaboration with Astellas on discovery and development of iADCs for up to three targets, includes an upfront payment of $90 million and $422.5 million...

STRO : 2.97 (+1.37%)
Sutro Biopharma to Present at the 2022 Wedbush PacGrow Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology...

STRO : 2.97 (+1.37%)
Sutro Biopharma Achieves “First in Human” Milestone in Cytokine Derivatives Collaboration with Merck

SOUTH SAN FRANCISCO, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage oncology...

STRO : 2.97 (+1.37%)
Sutro Biopharma Announces Virtual Deep Dive Research Forum: Next-Gen Innovations in ADCs

SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage oncology...

STRO : 2.97 (+1.37%)
Analysts’ Top Healthcare Picks: Ocular Therapeutix (OCUL), Syros Pharmaceuticals (SYRS)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ocular Therapeutix (OCUL – Research Report), Syros Pharmaceuticals (SYRS – Research Report) and Sutro...

OCUL : 6.90 (+0.88%)
STRO : 2.97 (+1.37%)
SYRS : 5.17 (+0.10%)
Wall Street Analysts Are Bullish on Top Healthcare Picks

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on 9 Meters Biopharma (NMTR – Research Report) and Sutro Biopharma (STRO – Research Report) with bullish...

NMTR : 0.0722 (-42.97%)
STRO : 2.97 (+1.37%)
Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)

- iADCs are a next-generation modality for treating cancer and designed to boost anti-cancer activity, offering potential new options for patients who do...

STRO : 2.97 (+1.37%)
Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503), (President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Sutro Biopharma, Inc. (NASDAQ: STRO), (CEO:...

STRO : 2.97 (+1.37%)
PCVX : 75.46 (-0.07%)
Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503), (President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Sutro Biopharma, Inc. (NASDAQ: STRO), (CEO:...

STRO : 2.97 (+1.37%)
PCVX : 75.46 (-0.07%)

Business Summary

Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in...

See More

Key Turning Points

3rd Resistance Point 3.30
2nd Resistance Point 3.17
1st Resistance Point 3.05
Last Price 2.97
1st Support Level 2.80
2nd Support Level 2.67
3rd Support Level 2.55

See More

52-Week High 6.13
Fibonacci 61.8% 4.55
Fibonacci 50% 4.07
Fibonacci 38.2% 3.58
Last Price 2.97
52-Week Low 2.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar